Andrew Ashe Biography and Net Worth

Insider of Verve Therapeutics

Andrew Ashe is president and chief operating officer of Verve Therapeutics. Mr. Ashe is an accomplished biotech executive with over 20 years of experience in operations and legal management. Prior to joining Verve, he served as a senior executive and general counsel for several biotech companies, including Applied Genetic Technologies Corporation and Dyax Corp. During his tenure at Dyax, Mr. Ashe managed all legal and administrative functions during a period of growth in which market capitalization increased from $180 million to $6 billion. While at Dyax, he also established more than 75 revenue-generating collaborations with biotech and pharma companies in the United States, Europe, India, Australia, and Japan. Dyax was acquired in 2016. Previously, Mr. Ashe was a member of the business law practices at Prince Lobel Tye LLP and Nutter, McClennen & Fish LLP. Prior to attending law school, he served as a trading specialist and senior analyst at the American and New York Stock Exchanges. He holds a B.A. in finance from the Isenberg School of Management at University of Massachusetts and a J.D. from the George Washington University School of Law.

What is Andrew D. Ashe's net worth?: The estimated net worth of Andrew D. Ashe is at least $1.89 million as of May 14th, 2024. Mr. Ashe owns 342,509 shares of Verve Therapeutics stock worth more than $1,894,075 as of December 18th. This net worth evaluation does not reflect any other investments that Mr. Ashe may own. Additionally, Mr. Ashe receives a salary of $703,850.00 as Insider at Verve Therapeutics. Learn More about Andrew D. Ashe's net worth.
How old is Andrew D. Ashe?: Mr. Ashe is currently 57 years old. There are 5 older executives and no younger executives at Verve Therapeutics. The oldest executive at Verve Therapeutics is Dr. Barry S. Ticho FACC, M.D., Ph.D., Co-Founder, who is 63 years old. Learn More on Andrew D. Ashe's age.
What is Andrew D. Ashe's salary?: As the Insider of Verve Therapeutics, Inc., Mr. Ashe earns $703,850.00 per year. There are 3 executives that earn more than Mr. Ashe. The highest earning executive at Verve Therapeutics is Dr. Sekar Kathiresan M.D., Co-Founder, CEO & Director, who commands a salary of $973,250.00 per year. Learn More on Andrew D. Ashe's salary.
How do I contact Andrew D. Ashe?: The corporate mailing address for Mr. Ashe and other Verve Therapeutics executives is , , . Verve Therapeutics can also be reached via phone at 617-603-0070 and via email at [email protected]. Learn More on Andrew D. Ashe's contact information.
Has Andrew D. Ashe been buying or selling shares of Verve Therapeutics?: Andrew D. Ashe has not been actively trading shares of Verve Therapeutics within the last three months. Most recently, on Tuesday, May 14th, Andrew D. Ashe bought 76,000 shares of Verve Therapeutics stock. The stock was acquired at an average cost of $6.26 per share, with a total value of $475,760.00. Following the completion of the transaction, the insider now directly owns 342,509 shares of the company's stock, valued at $2,144,106.34. Learn More on Andrew D. Ashe's trading history.
Who are Verve Therapeutics' active insiders?: Verve Therapeutics' insider roster includes Burt Adelman (Director), Andrew Ashe (Insider), Andrew Bellinger (Insider), and Sekar Kathiresan (CEO). Learn More on Verve Therapeutics' active insiders.
Are insiders buying or selling shares of Verve Therapeutics?: In the last twelve months, Verve Therapeutics insiders bought shares 1 times. They purchased a total of 76,000 shares worth more than $475,760.00. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 1,514 shares worth more than $12,475.36. The most recent insider tranaction occured on May, 14th when insider Andrew D Ashe bought 76,000 shares worth more than $475,760.00. Insiders at Verve Therapeutics own 19.3% of the company. Learn More about insider trades at Verve Therapeutics.
Information on this page was last updated on 5/14/2024.

Andrew D. Ashe Insider Trading History at Verve Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/14/2024	Buy	76,000	$6.26	$475,760.00	342,509
12/2/2021	Buy	4,000	$32.10	$128,400.00

Andrew D. Ashe Buying and Selling Activity at Verve Therapeutics

Verve Therapeutics Company Overview

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $5.09

$5.05

$5.59

50 Day Range

MA: $5.75

$4.50

$7.19

2 Week Range

Now: $5.09

$4.30

$19.34

Volume

2,051,953 shs

Average Volume

1,361,526 shs

Market Capitalization

$430.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.71

Uncover the Top Gold Stock of the Bull Market

From Huge Alerts | Ad

Gold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?

Click here to see how this opportunity could transform your portfolio.

Andrew Ashe Biography and Net Worth

What is Andrew D. Ashe's net worth?

How old is Andrew D. Ashe?

What is Andrew D. Ashe's salary?

How do I contact Andrew D. Ashe?

Has Andrew D. Ashe been buying or selling shares of Verve Therapeutics?

Who are Verve Therapeutics' active insiders?

Are insiders buying or selling shares of Verve Therapeutics?